Luis Campos
Interventional Cardiology · Houston, TXNPI 1952424962
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Gilead at 30.4% of the total. Reporting peaked in 2019 at $571 and has fallen 52.0% since, to $274 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 98 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$545
- E.r. Squibb & Sons, L.L.C.$223
- Pfizer$169
- GSK$165
- Incyte Corporation$115
- AVEO Pharmaceuticals, Inc.$114
- plus $464 from 13 others
What the payments were for
- Food & beverage$1,794100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 28 | $545 |
| E.r. Squibb & Sons, L.L.C. | 17 | $223 |
| Pfizer | 10 | $169 |
| GSK | 9 | $165 |
| Incyte Corporation | 6 | $115 |
| AVEO Pharmaceuticals, Inc. | 5 | $114 |
| Bayer | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| AstraZeneca | 2 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| Genentech USA, Inc. | 3 | $47 |
| Sanofi | 1 | $40 |
| Urogen Pharma, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Novartis | 1 | $15 |
| EMD Serono, Inc. | 1 | $13 |
How this compares
$1,794 in reported general payments places this provider in the 10th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.